



JAGSONPAL PHARMACEUTICALS LIMITED

Corporate Office: Nimai Tower, 3rd Floor, Plot No. 412-415, Phase-IV, Udyog Vihar, Gurugram -122015,
Haryana (India)

Ph.: +91 124 4406710; E-mail: cs@jagsonpal.com; Website: www.jagsonpal.com
CIN NO. L74899DL1978PLC009181

May 31, 2024

The Department of Corporate Services- Listing BSE Ltd, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001 Scrp Code: 507789	The Department of Corporate Services- Listing National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 Symbol: JAGSNPHARM
--	---

Sub: Update on 'Acquisition of India and Bhutan Business of Yash Pharma Laboratories Private Limited - Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

We refer to our intimation dated May 16, 2024 wherein we had informed that the Company had signed Business Transfer Agreement ("BTA") for the purchase of India & Bhutan business of Yash Pharma Laboratories Private Limited ("Yash Pharma") along with the brands and associated trademark and our press release titled "Jagsonpal Pharmaceuticals Limited to acquire India and Bhutan business of Yash Pharma Laboratories Private Limited".

We now wish to inform you that on completion of customary closing conditions, the transaction has now achieved closure. The acquired business shall be consolidated with the Company's financials with effect from June 01, 2024.

We request you to take the same on record.

Thanking you,

Yours faithfully,

For **Jagsonpal Pharmaceuticals Limited**

Abhishek Joshi
Company Secretary & Compliance Officer